Abstract
Adenylation domains CcbC and LmbC control the specific incorporation of amino acid precursors in the biosynthesis of lincosamide antibiotics celesticetin and lincomycin. Both proteins originate from a common L-proline-specific ancestor, but LmbC was evolutionary adapted to use an unusual substrate, (2S,4R)-4-propyl-proline (PPL). Using site-directed mutagenesis of the LmbC substrate binding pocket and an ATP-[32P]PPi exchange assay, three residues, G308, A207 and L246, were identified as crucial for the PPL activation, presumably forming together a channel of a proper size, shape and hydrophobicity to accommodate the propyl side chain of PPL. Subsequently, we experimentally simulated the molecular evolution leading from L-proline-specific substrate binding pocket to the PPL-specific LmbC. The mere change of three amino acid residues in originally strictly L-proline-specific CcbC switched its substrate specificity to prefer PPL and even synthetic alkyl-L-proline derivatives with prolonged side chain. This is the first time that such a comparative study provided an evidence of the evolutionary relevant adaptation of the adenylation domain substrate binding pocket to a new sterically different substrate by a few point mutations. The herein experimentally simulated rearrangement of the substrate binding pocket seems to be the general principle of the de novo genesis of adenylation domains’ unusual substrate specificities. However, to keep the overall natural catalytic efficiency of the enzyme, a more comprehensive rearrangement of the whole protein would probably be employed within natural evolution process.
Highlights
Lincosamides are a small but clinically important group of antibiotics consisting of only two compounds with a characterised biosynthetic gene cluster, lincomycin and celesticetin (Fig 1A), produced by Streptomyces lincolnensis and Streptomyces caelestis, respectively
The crucial step of lincosamide biosynthesis is the condensation of amino sugar and amino acid precursors via an amide bond [1]
LmbC substrate binding pocket (SBP) mutagenesis: Detection of residues affecting the affinity for PPL
Summary
Lincosamides are a small but clinically important group of antibiotics consisting of only two compounds with a characterised biosynthetic gene cluster, lincomycin and celesticetin (Fig 1A), produced by Streptomyces lincolnensis and Streptomyces caelestis, respectively. The PPL precursor is recognised and activated by A-domain LmbC, while the homologous protein CcbC from celesticetin biosynthesis is strictly L-proline-specific [3].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.